E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe or moderately severe hemophilia A (baseline factor VIII ≤ 2% of normal) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060612 |
E.1.2 | Term | Hemophilia A |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours) with that of pharmacokinetics (PK)-driven prophylaxis (20-80 IU/kg every 72 ± 6 hours) |
|
E.2.2 | Secondary objectives of the trial |
2. To compare the rate of bleeding episodes for the on-demand regimen and the prophylaxis regimens 3. To compare the total weight adjusted consumption of ADVATE rAHF-PFM on each regimen 4. To determine the efficacy of ADVATE rAHF-PFM in the control of bleeding episodes throughout the study 5. To determine the pharmacokinetic parameters for ADVATE rAHF-PFM utilizing at least 3 lots of the product 6. To determine the immunogenicity of ADVATE rAHF-PFM 7. To determine the safety and toxicity of ADVATE rAHF-PFM 8. To determine differences in Health-Related Quality of Life (HRQoL) between the 2 prophylaxis regimens and changes between the on-demand treatment and prophylaxis regimens. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The subject or the subject’s legally authorized representative has provided written informed consent. 2. The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level ≤ 2% of normal, as tested at screening.iv 3. The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant). 4. The subject is within 7 to 65 years of age. 5. The subject has a Karnofsky performance score > 60. 6. The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a stable CD4 count ≥ 400 cells/mm³ (CD4 count determined at screening if necessary). 7. The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment. 8. The subject has a documented history (e.g., in medical charts, dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment. 9. The subject resides within the coverage area of the mobile compliance device (Section 12.6); coverage area will be determined at screening. |
|
E.4 | Principal exclusion criteria |
1. The subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins. 2. The subject has a history of factor VIII inhibitors with a titer ≥ 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening. 3. The subject has a detectable factor VIII inhibitor at screening, with a titer ≥ 0.4 BU (by Nijmegen Assay) in the central laboratory. 4. The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices. 5. The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand’s Disease). 6. The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug. 7. The subject has participated in another investigational study within 30 days of enrollment. 8. The subject has previously participated in a clinical study with ADVATE rAHF PFM. 9. The subject’s clinical condition may require a moderate or major surgery (i.e. requiring more study product than allowed by the protocol) during the period of the subject’s participation in the study. 10. The subject is female of childbearing potential with a positive pregnancy test. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Yearly transformed rate of bleeding episodes estimated from each arm of the 1 year prophylactic regimen |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined in the protocol. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 10 |